Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Modesto

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Journal of Medical Economics|January 27, 2021
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in GermanyAditya Sardesai, Axel Dignass, Peter Quon, et al.
Advances in Therapy|July 31, 2023
Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical ProgramMichael Chiorean, Marco Daperno, Charlie W Lees, et al.
Clinical Pharmacology and Therapeutics|April 5, 2022
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance StudiesArnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, et al.
Inflammatory Bowel Diseases|December 16, 2020
Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD RegistryManasi Agrawal, Erica J Brenner, Xian Zhang, et al.
Therapeutic Advances in Gastroenterology|December 12, 2022
Modified Mayo score <i>versus</i> Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE programWilliam J Sandborn, Bruce E Sands, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|November 7, 2023
An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum PostsDavid T Rubin, Joana Torres, Iris Dotan, et al.
Alimentary Pharmacology & Therapeutics|October 9, 2021
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitisDavid T Rubin, Irene Modesto, Séverine Vermeire, et al.
Gastroenterology|October 1, 2008
Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's diseaseSara Renna, Calogero Cammà, Irene Modesto, et al.
Expert Review of Gastroenterology & Hepatology|June 16, 2021
Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature reviewMarla C Dubinsky, Iris Dotan, David T Rubin, et al.
Gastroenterology Research and Practice|October 25, 2012
The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literatureEmanuele Sinagra, Emma Aragona, Claudia Romano, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Journal of Medical Economics|January 27, 2021
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in GermanyAditya Sardesai, Axel Dignass, Peter Quon, et al.
Advances in Therapy|July 31, 2023
Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical ProgramMichael Chiorean, Marco Daperno, Charlie W Lees, et al.
Clinical Pharmacology and Therapeutics|April 5, 2022
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance StudiesArnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, et al.
Inflammatory Bowel Diseases|December 16, 2020
Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD RegistryManasi Agrawal, Erica J Brenner, Xian Zhang, et al.
Therapeutic Advances in Gastroenterology|December 12, 2022
Modified Mayo score <i>versus</i> Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE programWilliam J Sandborn, Bruce E Sands, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|November 7, 2023
An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum PostsDavid T Rubin, Joana Torres, Iris Dotan, et al.
Alimentary Pharmacology & Therapeutics|October 9, 2021
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitisDavid T Rubin, Irene Modesto, Séverine Vermeire, et al.
Gastroenterology|October 1, 2008
Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's diseaseSara Renna, Calogero Cammà, Irene Modesto, et al.
Expert Review of Gastroenterology & Hepatology|June 16, 2021
Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature reviewMarla C Dubinsky, Iris Dotan, David T Rubin, et al.
Gastroenterology Research and Practice|October 25, 2012
The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literatureEmanuele Sinagra, Emma Aragona, Claudia Romano, et al.
Pageof 5